Brief Article
Copyright ©2011 Baishideng Publishing Group Co.
World J Gastroenterol. Jan 28, 2011; 17(4): 506-513
Published online Jan 28, 2011. doi: 10.3748/wjg.v17.i4.506
Table 1 Patient characteristics
Gender (M:F)18:14
Age of CD diagnosis: median in years (range)58.5 (38-74)
Age of RCDII diagnosis: median in years (range)64 (42-78)
Age at the start of 2-CdA treatment: median in years (range)64 (45-78)
Treatment prior to 2-CdA
None22
Immunosuppressive drugs10
Follow-up time: median in months (range)31 (4-120)
HLA-DQ status
DQ2 heterozygous17
DQ2 homozygous12
DQ2 and DQ82
Unknown1
TCR-γ gene rearrangement
Monoclonal18
Polyclonal9
Unknown5
Marsh classification before 2-CdA
Marsh IIIA13
Marsh IIIB11
Marsh IIIC8
Intestinal aberrant IELs before 2-CdA: median in % (range)61 (21-96)
Body mass index before 2-CdA: median in kg/m2 (range)21 (16-27)
Albumin level before 2-CdA: median (range, reference value 35-52 g/L)36 (23-47)
Haemoglobin level before 2-CdA: median in mmol/L (range)7.8 (6.0-9.8)
Table 2 The 1- and 2-yr response rates and the median time to response in the pre-treated (I) and the upfront 2-CdA (II) group
Treatment(n)Response (%)
Time to a 50% response rate (mo)
12 mo24 mo
Histological responseGroup I10132536
Group II22205824
Overall32104736 (3-96)
Immunological1 responseGroup I101111> 60
Group II22525812
Overall32394141 (2-96)
Clinical2 responseGroup I1067676
Group II2295953
Overall3281813 (2-72)
Overall responseGroup I10223836
Group II22284330
Overall32254136